Population Pharmacokinetic Analysis and Pharmacodynamic Evaluation of Sulbactam in Pediatric Patients: Dosing Suggestions for Acinetobacter baumannii Infections
Journal of the Pediatric Infectious Diseases Society · 13.05.2025 · 14 (5)
DOI: 10.1093/jpids/piaf043 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Pediatric Infectious Diseases Society, online erschienen am 20.05.2025. Verfasst von Tetsushu Onita und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Shimane University Hospital, Shimane 693-8501, Japan. Hauptthemen laut MEDLINE: Sulbactam, Acinetobacter baumannii, Acinetobacter Infections, Anti-Bacterial Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
This study aims to develop a population pharmacokinetic (PK) model of sulbactam in pediatric patients using pooled data analysis, and to optimize dosing regimens against Acinetobacter baumannii infections.
Methods
Publications were systematically identified with MEDLINE for collecting sulbactam PK data in pediatric patients. Sulbactam PK model was developed using plasma concentration–time data gained from identified literature works. Based on the model, we estimated the probability of attaining the pharmacodynamic (PD) target against A. baumannii.
Results
The data were adequately described by 2-compartment model. Age was a statistically significant covariate in clearance. Aiming for the PD target of 60% of time above minimum inhibitory concentration in free drug concentrations (fT > MIC), the breakpoint MICs were increased by extending infusion time from 0.5 to 4 hours. The breakpoint MICs for 4-hour infusion regimens of 25 mg/kg 4 times daily (100 mg/kg/day) achieved 4 μg/mL in infants (4 weeks to 11 months), children (1–6 years old) and pediatrics (7–16 years old). The breakpoint values for 4-hour infusions of 50 mg/kg 4 times daily (200 mg/kg/day) achieved 8 μg/mL (intermediate range of Clinical and Laboratory Standards Institute criteria) in all age groups.
Conclusions
This population PK analysis and PD evaluation suggest that higher dosing regimen, especially with extended infusion time, should be reasonable for treating A. baumannii infections in pediatric patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Shimane University Hospital, Shimane 693-8501, Japan.
- Department of Clinical Pharmacotherapy, Hiroshima University, Hiroshima 734-8551, Japan.
ORCID-Profile: Tetsushu Onita
Zitieren
APA
Onita, T., Sano, Y., Ikawa, K., Ishihara, N., Tamaki, H., & Yano, T. (2025). Population Pharmacokinetic Analysis and Pharmacodynamic Evaluation of Sulbactam in Pediatric Patients: Dosing Suggestions for Acinetobacter baumannii Infections. Journal of the Pediatric Infectious Diseases Society, 14(5). https://doi.org/10.1093/jpids/piaf043
Vancouver
Onita T, Sano Y, Ikawa K, Ishihara N, Tamaki H, Yano T. Population Pharmacokinetic Analysis and Pharmacodynamic Evaluation of Sulbactam in Pediatric Patients: Dosing Suggestions for Acinetobacter baumannii Infections. Journal of the Pediatric Infectious Diseases Society. 2025;14(5). doi:10.1093/jpids/piaf043
BibTeX
@article{Onita2025,
author = {Onita, Tetsushu and Sano, Yui and Ikawa, Kazuro and Ishihara, Noriyuki and Tamaki, Hiroki and Yano, Takahisa},
title = {Population Pharmacokinetic Analysis and Pharmacodynamic Evaluation of Sulbactam in Pediatric Patients: Dosing Suggestions for Acinetobacter baumannii Infections},
journal = {Journal of the Pediatric Infectious Diseases Society},
year = {2025},
volume = {14},
number = {5},
doi = {10.1093/jpids/piaf043}
}
EUVIMED